CONTEMPORARY THERAPEUTIC DEVELOPMENTS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Keywords:
Χρόνια Φλεγμονώδης Απομυελινωτική Πολυνευροπάθεια , Θεραπεία, Ανοσοθεραπεία, Ενδοφλέβια Ανοσοσφαιρίνη , Υποδόρια Ανοσοσφαιρίνη , Κορτικοστεροειδή,Abstract
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a debilitating autoimmune disorder that is
treatable with multiple therapeutic options. Despite its responsiveness to treatment, frequent misdiagnoses
complicate effective management. Various agents can be utilized as first and second-line. First-line options
are intravenous immunoglobulin, corticosteroids and plasma exchange. Second-line therapies, often
immunosuppressants, are employed either as alternatives to steroids or as enhanced treatment strategies
for more severe cases. Recent advancements have introduced new therapeutic targets, such as Fc receptor
blockers, that are now approved and available, significantly expanding treatment possibilities. This evolving
landscape highlights the shift towards personalized medicine in CIDP management, promising improved
outcomes through tailored therapeutic approaches that are specifically adapted to individual patient profile
